Professor Heather Payne is a Consultant Clinical Oncologist, specialising in urological and prostate cancer at University College London Hospitals NHS Trust and she also sees patients privately, including at The Harley Street Clinic and The Prostate Centre.

Professor Payne trained at St Mary’s Hospital and after qualifying, spent time in general medicine in London and Haiti.

On her returned to London, she trained as a Clinical Oncologist, and also developed an interest in urological oncology.

In addition to her clinical work, she is also actively involved in research, and she has pioneered a program of high-dose rate brachytherapy for prostate cancer. Current research interests include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer, chemotherapy and assisting men with decision making and prostate cancer.

Professor Payne is principal investigator in a number of international and national studies and has been published in peer-reviewed journals. She is Chair of the British Uro-oncology Group and Oncology Lead for the National Prostate Cancer Audit. She also serves on the Prostate Cancer Advisory Group for the UK.

Diseases, Medical Tests and Treatments

• External Beam Radiotherapy
• Intensity Modulated Radiotherapy/Rapid Arc
• Low Does Brachytherapy
• Hormone Treatment
• Prostate Cancer
• Novel Hormone Therapy
• External beam radiotherapy
• Chemotherapy
• Brachytherapy
• 
  

Dr Mary McCormack is a Consultant Clinical Oncologist, specialising in gynaecological andf breast cancers. She qualified in medicine from Guy's and St Thomas' Hospital. Before medical school, she undertook research in radiation biology and was awarded a PhD in 1989. Dr McCormack has worked in leading London cancer centres and in 2000, she was awarded the FRCR in clinical oncology. She was appointed a consultant at University College London Hospital in 2002.

Dr McCormack treats all subtypes of gynaecological cancer, including ovary, womb, uterus, cervix, vulva, vagina and also treats breast cancer. Treatments include chemotherapy, targeted/ biological therapy,radiotherapy and brachytherapy. She has a particular interest in cervical cancer treatment and targeted agents in breast, ovarian and endometrial cancer. Dr McCormack is a major contributor to national and international clinical trials and is the chief investigator on a nuber of studies. She is the current chair of the international Cervical Cancer Research Network (CCRN)and an exective member of the Gynaecologic Cancer Intergroup (GCIG)and a member of the International Gynaecologic Cancer Society's education committee.She is also a member of the ASCO International Affairs Committee.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Radiotherapy
• Chemotherapy
• Brachytherapy

• Cervical Cancer
• Breast Cancer
• Gynaecological Cancers
• uterine cancer
• vaginal and vulval cancer
• ovary cancer
• chemotherapy 
• biological therapy
• radiotherapy

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital. 

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papaers and presented at national and international conferences.

• Chemotherapy
• Immunotherapy
• Biological Therapy
• Genetic Testing

• Liver Cancer
• Biliary Cancer
• Bowel Cancer
• Colorectal Cancer
• Oesophageal Cancer
• Pancreatic Cancer

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

Diseases, Medical Tests and Treatments

• Cancer prevention and screening 
• Chemotherapy 
• Brain cancer 
• Neuro-endocrine tumours 
• Central nervous system cancer 
• Novel agents 

Dr Sarah Harris has been a Consultant Clinical Oncologist working at Guy’s and St Thomas’ NHS Trust for over 20 years. She now only sees patients privately at a range of private centres across London as well as by remote video consultation . Her areas of interests include breast cancer, prostate cancer and urological cancer, and she treats these conditions using radiotherapy and chemotherapy in central London and the south east of England.

She has extensive clinical experience in the management of breast cancer using radiotherapy and drug treatments. She has a specialist interest in technical radiotherapy due to its maximal benefits and reduced side effects. In particular she uses heart sparing radiotherapy techniques for left-sided breast radiotherapy. Furthermore, she regularly uses stereotactic radiotherapy for the treatment of localised recurrent cancers using the latest radiotherapy technologies, cyberknife and SABR. For the treatment of prostate cancer, she can perform external radiotherapy using modern IMRT and IGRT.

Along with her wealth of experience, she completed specialist training in proton beam radiotherapy at the University Of Pennsylvania in 2020. Dr Harris also holds many professional memberships, including the Royal College of Physicians and the Royal College of Radiologists.

In her leisure time , she is a keen golfer aspiring to a single figure handicap.

• Radiotherapy
• Chemotherapy
• CyberKnife therapy
• Stereotactic Ablative Radiotherapy (SABR)
• Proton beam radiotherapy

• Breast Cancer
• Prostate Cancer
• Urological Cancers

Dr Stephen Morris is a consultant in Clinical Oncology at Guy's and St Thomas' Hospitals, specialising in the management of skin and urological cancers. He specialises in brachytherapy, external beam radiotherapy and chemotherapy for prostate cancer at Guys Hospital. He also leads the chemotherapy and radiotherapy service for cutaneous lymphoma at the St Johns Institute of dermatology at Guys.

Dr Morris completed his initial medical training at Guy's and St Thomas' medical school. Following this, he trained in clinical oncology at the Royal Marsden Hospital and the Guy's and St Thomas' Cancer Centre. At Guys he was involved in setting up the dynamic prostate brachytherapy service and since his appointment as a consultant, has continued to innovate in the field, working for ever-improving outcomes for patients.

In addition to his work in research and clinical trials, he has led the design and implementation of a new modern Total Skin Electron Beam technique for cutaneous lymphoma, IMRT and IGRT for prostate cancer and more recently has developed and implemented the use of the SpaceOAR and Auto Beam Hold intra fraction IGRT technique for prostate cancer. Dr Morris is also a keen teacher and involved in education as a tutor for clinical oncology.

• Prostate brachytherapy
• Radiotherapy
• Chemotherapy
• Clinical Trials

• Urological oncology 
• Dermatological oncology
• Cutaneous lymphoma and melanoma
• Prostate cancer

Dr Thomas Newsom-Davis a Consultant Medical Oncologist at Chelsea and Westminster Hospital. He specialises in thoracic malignancies, especially lung cancer and mesothelioma. In 2015, he was awarded the Macmillan Innovation Excellence Award.

Training

Dr Newsom-Davis completed his training at University College and Middlesex School of Medicine, London, in 1998, including First Class honours for his BSc. He went on specialise in medical oncology at Charing Cross and Hammersmith Hospitals and completed a PhD in tumour immunology. He was appointed to Chelsea & Westminster Hospital in 2010.

Current Roles

Dr Newsom-Davis leads the lung cancer service for Chelsea & Westminster Hospital, and is Vice Chair of the British Thoracic Oncology Group (BTOG) Steering Committee, an organistion which supports and educates thoracic oncology profressionals across the United Kingdom. Dr Newsom-Davis is Chair of the Harley Street Clinic lung cancer multidisciplinary team (MDT), and Chair of the HCA Healthcare UK Thoracic Oncology Board.

Research

Dr Newsom-Davis has an active clinical trial portfolio, and has presented his work at National and International meetings. He has been an invited lecturer for organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

• Immunotherapy, Targeted Therapy, Chemotherapy
• Lung Cancer
• Mesothelioma

Dr Amen Sibtain is a Consultant Clinical Oncologist specialising in the management of Gastrointestinal, Hepatobiliary and Head and Neck cancers with chemotherapy and radiotherapy. He is also highly experienced in chemo-radiotherapy, state of the art radiotherapy techniques, including VMAT, stereotactic radiotherapy and radiosurgery, and intraoperative radiotherapy.

Dr Sibtain is presently the Clinical Director of GI oncology and Radiotherapy at St Bartholomew’s Hospital, an examiner in oncology for the Royal College of Radiologists, a member of the medical advisory panel for both Macmillan and CRUK, oncology advisor for BBC Drama and the Clinical Lead in Head and Neck Cancer at Barts. Dr Sibtain was previously President of the Oncology Section of the Royal Society of Medicine, Programme Director for Clinical Oncology Specialist Training Committee for the London Deanery and Chairman of the Head and Neck Tumour Board for North East London. He also previously worked at the Royal Marsden, Mount Vernon and The Middlesex Hospitals, before he took up his post at Barts. He was awarded an MD degree for his research in tumour hypoxia by the University of London.

As well as his clinical work he remains actively involved in research. He has been published in a number of peer-reviewed journals and edited the books Towards the Prevention of Cancer (2007) and Physics for Clinical Oncologists (2012).

Diseases, Medical Tests and Treatments

• Chemotherapy
• Cyberknife Therapy
• Intensity Modulated Radiotherapy 
• Radio Surgery
• Radiotherapy
• Rapid Arc
• Stereotactic Radiotherapy 
• Volumetric Arc Radiotherapy 
• Anal Cancer
• Bilary Cancer
• Bowel Cancer  
• Colon Cancer
• Gastro-Intestinal Cancers
• Head & Neck Cancers
• Liver Cancer
• Oesophageal Cancer
• Pancreatic Cancer
• Rectal Cancer
• Stomach Cancer

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Dr. John Conibear completed his initial medical training at the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006. Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship, he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded an MD(Res) from UCL in 2018.

Dr. Conibear is currently deputy medical director and deputy director of Barts Cancer Centre. Dr Conibear specialises in all the non-surgical treatments for both lung and breast cancers. He has expertise in chemotherapy, biological therapy, immunotherapy, radiotherapy and state of the art radiotherapy techniques including deep inspiration breath-hold (DIBH) for early breast cancer, Intensity Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), 4D-CT and both Cyberknife and Gamma Knife (stereotactic radiotherapy). He is also currently the lead for chemotherapy and clinical director for thoracic oncology in St. Bartholomew’s Hospital in addition to his private practice.

• Chemotherapy
• Deep Inspiration Breath Hold
• Gamma Knife
• Image-guided radiotherapy (IGRT)
• Immunotherapy
• Intensity modulated radiotherapy (IMRT)
• Radiotherapy

• Breast cancer
• Lung cancer

Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.

Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.

He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.

Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.

He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.

Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Chemotherapy 
• Immunotherapy 

• Breast Cancer
• Lung Cancer